Download PDF
Exp Clin Endocrinol Diabetes 2014; 122(05): 261-267
DOI: 10.1055/s-0034-1372578
Mini-Review
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Phosphatidylinositide-3 Kinase: A Newer Molecular Target in Metabolic and Hormonal Pathway of Polycystic Ovary Syndrome

K. N. Shah
1   Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India
,
S. S. Patel
1   Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India
› Author Affiliations
Further Information

Publication History

received 04 December 2013
first decision 05 February 2014

accepted 18 March 2014

Publication Date:
07 April 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Polycystic ovary syndrome is characterized by hyperandrogenemia, hyperinsulinemia and/or abnormal ovulation, which are the 3 main consequences of polycystic ovary syndrome. The occurrence of polycystic ovary syndrome is higher and 1 out of 45 women gets affected by this disorder. The pathophysiology of polycystic ovary syndrome is very unique, and many hormonal and metabolic changes occur at molecular level. Polycystic ovary syndrome is a hormonal disorder that affects multiple organ systems within the body, which is caused by insensitivity to the hormone insulin. The target organs of insulin action are skeletal muscles, adipose tissue, fibroblasts where metabolic actions of insulin take place. In polycystic ovary syndrome condition, due to insulin resistance, the actions like glucose uptake and glycogen synthesis gets declined along with exhibiting steroidogenic effect in ovaries. The action of phophatidylinositide-3 kinase varies in different tissues. It plays major role in several kinases. The inhibition and activation of phophatidylinositide-3 kinase in different tissues results in differential outcomes. The inhibition of phophatidylinositide-3 kinase in ovary leads to decreased androgen synthesis and the activation affects the positive actions of insulin like glucose uptake. Targeting the hyperandrogenemia of polycystic ovary syndrome, we can get more ameliorating action in polycystic ovary syndrome because glucose uptake, which is mediated by phophatidylinositide-3 kinase activation, is not much altered during polycystic ovary syndrome as much as the androgen levels in polycystic ovary syndrome. Therefore, it is beneficial to control the androgen level. Thus, phophatidylinositide-3 kinase inhibition can be a promising target in the treatment of polycystic ovary syndrome.

Key words

hyperandrogenemia - insulin resistance - phosphatidylinositol-3 kinase - polycystic ovary syndrome (PCOS)
 

  • References

  • 1 Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 2003; 46: 325-340
    CrossrefPubMedSearch in Google Scholar
  • 2 Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010; 8: 41-51
    CrossrefPubMedSearch in Google Scholar
  • 3 Gordon JD, Rydfors J, Druzin M et al. Reproductive endocrinology. In: Gordon JD. (ed.) Obstetrics, Gynecology and Infertility, Handbook for clinicians. Virginia: ScrubHill Press; 2007: 492-506
    Search in Google Scholar
  • 4 The Rotterdam ESHRE ASRM-sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25
    PubMedSearch in Google Scholar
  • 5 Diamanti-Kandarakis E, Kandarakis H, Legro RS. The role of genes and environment in the etiology of PCOS. Endocrine 2006; 30: 19-26
    CrossrefPubMedSearch in Google Scholar
  • 6 Strauss 3rd JF. Some new thoughts on the pathophysiology and genetics of polycystic ovary syndrome. Ann N Y Acad Sci 2003; 997: 42-48
    CrossrefPubMedSearch in Google Scholar
  • 7 Amato P, Simpson JL. The genetics of polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004; 18: 707-718
    CrossrefPubMedSearch in Google Scholar
  • 8 O’Meara NM, Blackman JD, Ehrmann DA et al. Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993; 76: 1241-1247
    PubMedSearch in Google Scholar
  • 9 Dunaif A, Xia J, Book CB et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995; 96: 801-810
    CrossrefPubMedSearch in Google Scholar
  • 10 Poretsky L, Smith D, Seibel M et al. Specific insulin binding sites in human ovary. J Clin Endocrinol Metab 1984; 59: 809-811
    CrossrefPubMedSearch in Google Scholar
  • 11 Virkamäki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 1999; 103: 931-943
    CrossrefPubMedSearch in Google Scholar
  • 12 Cheatham B, Kahn CR. Insulin action and the insulin signaling network. Endocr Rev 1995; 16: 117-142
    CrossrefPubMedSearch in Google Scholar
  • 13 Cantrell DA. Phosphoinositide 3-kinase signalling pathways. J Cell Sci 2001; 114: 1439-1445
    PubMedSearch in Google Scholar
  • 14 Lawrence JCJ, Roach PJ. New insight into the role and mechanism of glycogen synthase activation by insulin. Diabetes 1997; 46: 541-547
    CrossrefPubMedSearch in Google Scholar
  • 15 Saltiel AR. Diverse signaling pathways in the cellular actions of insulin. Am J Physiol 1996; 270: E375-E385
    PubMedSearch in Google Scholar
  • 16 White MF, Yenush L. The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. Curr Top Microbiol Immunol 1998; 228: 179-208
    PubMedSearch in Google Scholar
  • 17 Vanhaesebroeck B, Leevers SJ, Ahmadi K et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001; 70: 535-602
    CrossrefPubMedSearch in Google Scholar
  • 18 Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657
    CrossrefPubMedSearch in Google Scholar
  • 19 Stephens LR, Eguinoa A, Erdjument-Bromage H et al. The Gbc sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell 1997; 89: 105-114
    CrossrefPubMedSearch in Google Scholar
  • 20 Dowler S, Currie RA, Campbell DG et al. Identification of pleckstrin-homology-domain-containing proteins with novel phosphoinositide-binding specificities. Biochem J 2000; 351: 19-27
    CrossrefPubMedSearch in Google Scholar
  • 21 Rohrschneider LR, Fuller JF, Wolf I et al. Structure, function and biology of SHIP proteins. Genes Dev 2000; 14: 505-520
    PubMedSearch in Google Scholar
  • 22 Wishart MJ, Dixon JE. PTEN and myotubularin phosphatases: from 3-phosphoinositide dephosphorylation to disease. Trends Cell Biol 2002; 12: 579-585
    CrossrefPubMedSearch in Google Scholar
  • 23 Dunaif A, Segal KR, Shelley DR et al. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992; 41: 1257-1266
    CrossrefPubMedSearch in Google Scholar
  • 24 Ciaraldi TP, El-Roeiy A, Madar Z et al. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 1992; 75: 577-583
    PubMedSearch in Google Scholar
  • 25 Ciaraldi TP, Morales AJ, Hickman MG et al. Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity. J Clin Endocrinol Metab 1997; 82: 1421-1425
    PubMedSearch in Google Scholar
  • 26 Lystedt E, Westergren H, Brynhildsen J et al. Subcutaneous adipocytes from obese hyperinsulinemic women with polycystic ovary syndrome exhibit normal insulin sensitivity but reduced maximal insulin responsiveness. Eur J Endocrinol 2005; 153: 831-835
    CrossrefPubMedSearch in Google Scholar
  • 27 Rosenbaum D, Haber R, Dunaif A. Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT4 glucose transporters in adipocytes. Am J Physiol 2003; 264: E197-E202
    PubMedSearch in Google Scholar
  • 28 Diamanti-Kandarakis E, Papavasiliou A. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med 2006; 12: 324-332
    CrossrefPubMedSearch in Google Scholar
  • 29 Goodarzi MO, Antoine HJ, Pall M et al. Preliminary evidence of glycogen synthase kinase 3 beta as a genetic determinant of the polycystic ovary syndrome. Fertil Steril 2007; 87: 1473-1476
    CrossrefPubMedSearch in Google Scholar
  • 30 Cortón M, Botella-Carretero JI, Bengurıa A et al. Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92: 328-337
    CrossrefPubMedSearch in Google Scholar
  • 31 Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800
    CrossrefPubMedSearch in Google Scholar
  • 32 Taylor SI, Cama A, Accili D et al. Mutations in the Insulin Receptor Gene. Endocr Rev 1992; 13: 566-595
    CrossrefPubMedSearch in Google Scholar
  • 33 Hotamisligil GS, Peraldi P, Budavari A et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665-668
    CrossrefPubMedSearch in Google Scholar
  • 34 Maddux BA, Sbraccia P, Kumakura S et al. Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. Nature 1995; 373: 448-451
    CrossrefPubMedSearch in Google Scholar
  • 35 Griffin ME, Marcucci MJ, Cline GW et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 1999; 48: 1270-1274
    CrossrefPubMedSearch in Google Scholar
  • 36 Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1999; 84: 3110-3116
    CrossrefPubMedSearch in Google Scholar
  • 37 DeFronzo RA, Jacot E, Jequier E et al. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 1981; 30: 1000-1007
    CrossrefPubMedSearch in Google Scholar
  • 38 Corbould A, Kim YB, Youngren JF. Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab 2005; 288: E1047-E1054
    PubMedSearch in Google Scholar
  • 39 Holman A, Svedberg J, Jennische E et al. Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am J Physiol 1990; 259: E555-E560
    PubMedSearch in Google Scholar
  • 40 Manneras L, Cajander S, Holman A et al. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology 2007; 148: 3781-3791
    CrossrefPubMedSearch in Google Scholar
  • 41 Dunaif A, Wu X, Lee A et al. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab 2001; 281: E392-E399
    PubMedSearch in Google Scholar
  • 42 Nestler JE, Jakubowicz DJ, de Vargas AF et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998; 83: 2001-2005
    CrossrefPubMedSearch in Google Scholar
  • 43 Willis D, Franks S. Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. J Clin Endocrinol Metab 1995; 80: 3788-3790
    CrossrefPubMedSearch in Google Scholar
  • 44 Cara JR, Rosenfield RL. Insulin-like growth factor I and insulin potentiate luteinizing hormone induced androgen synthesis by rat ovarian thecal interstitial cells. Endocrinology 1988; 123: 733-739
    CrossrefPubMedSearch in Google Scholar
  • 45 Buyalos RP. Insulin-like growth factor binding proteins in disorders of androgen excess. Sem Reprod Endocrinol 1994; 12: 21-25
    Thieme ConnectPubMedSearch in Google Scholar
  • 46 Romero G, Garmey JC, Veldhuis JD. The involvement of inositol phosphoglycan mediators in the modulation of steroidogenesis by insulin and insulin-like growth factor-I. Endocrinology 1993; 132: 1561-1568
    PubMedSearch in Google Scholar
  • 47 Nestler JE. Role of obesity and insulin in the development of anovulation. In: Filicori M, Flamigni C. (ed.) Ovulation Induction: Basic Science and Clinical Advances. Amsterdam: Elsevier; 1994: 103-114
    Search in Google Scholar
  • 48 Unger JW, Livingston JN, Moss AM. Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Prog Neurobiol 1991; 36: 343-362
    CrossrefPubMedSearch in Google Scholar
  • 49 Burger CW, Korsen T, Van Kessel H. Pulsatile luteinizing hormone patterns in the follicular phase of the menstrual cycle, polycystic ovarian disease (PCOD) and non-PCOD secondary amenorrhea. J Clin Endocrinol Metab 1985; 61: 1126-1132
    CrossrefPubMedSearch in Google Scholar
  • 50 Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med 2006; 12: 324-332
    CrossrefPubMedSearch in Google Scholar
  • 51 Munir I, Yen H, Geller DH et al. Insulin augmentation of 17a-hydroxylase activity is mediated by phosphatidyl inositol 3-kinase but not extracellular signal-regulated kinase-1/2 in human ovarian theca cells. Endocrinology 2004; 145: 175-183
    CrossrefPubMedSearch in Google Scholar
  • 52 Nelson-Degrave VL, Wickenheisser JK, Hendricks KL et al. Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome. Mol Endocrinol 2005; 19: 379-390
    CrossrefPubMedSearch in Google Scholar
  • 53 Poretsky L, Seto-Young D, Shrestha A et al. Phosphatidyl-inositol-3 kinase-independent insulin action pathway(s) in the human ovary. J Clin Endocrinol Metab 2001; 86: 3115-3119
    CrossrefPubMedSearch in Google Scholar
  • 54 Seto-Young D, Zajac J, Liu HC et al. The role of mitogen-activated protein kinase in insulin and insulin-like growth factor I (IGF-I) signaling cascades for progesterone and IGF-binding protein-1 production in human granulosa cells. J Clin Endocrinol Metab 2003; 88: 3385-3391
    CrossrefPubMedSearch in Google Scholar
  • 55 Flores JA, Garmey JC, Nestler JE et al. Sites of inhibition of steroidogenesis by activation of protein kinase-C in swine ovarian (granulosa) cells. Endocrinology 1993; 132: 1983-1990
    PubMedSearch in Google Scholar
  • 56 Greisen S, Ledet T, Ovesen P. Effects of androstenedione, insulin and luteinizing hormone on steroidogenesis in human granulosa luteal cells. Hum Reprod 2001; 16: 2061-2065
    CrossrefPubMedSearch in Google Scholar
  • 57 Sekar N, Lavoie HA, Veldhuis JD. Concerted regulation of steroidogenic acute regulatory gene expression by luteinizing hormone and insulin (or insulin-like growth factor I in primary cultures of porcine granulosa luteal cells. Endocrinology 2000; 141: 3983-3992
    PubMedSearch in Google Scholar
  • 58 Erickson GF, Magoffin DA, Cragun JR et al. The effects of insulin and insulin-like growth factors-I and -II on estradiol production by granulosa cells of polycystic ovaries. J Clin Endocrinol Metab 1990; 70: 894-902
    CrossrefPubMedSearch in Google Scholar
  • 59 Bals-Pratsch M, Grober B, Seifert B et al. Early Onset and High Prevalence of Gestational Diabetes in PCOS and Insulin Resistant Women Before and After Assisted Reproduction. Exp Clin Endocrinol Diabetes 2011; 119: 338-342
    Thieme ConnectPubMedSearch in Google Scholar
  • 60 Moeini A, Mansoori M, Eslami B et al. Evaluating Endometrial Hyperplasia in Infertile Women with Polycystic Ovarian Syndrome in Roointan-Arash Hospital. J Reprod Infertil 2008; 8: 330-336
    PubMedSearch in Google Scholar
  • 61 Temple KA, Watson S, Whitmore H et al. Obstructive Sleep Apnea in Women with Polycystic Ovary Syndrome Increases the Risk of Abnormal Glucose Tolerance. Endocr Rev 2012; 33: 47-54
    PubMedSearch in Google Scholar
  • 62 Hachmi BSL, Hachmi BSS, Bouzid C et al. Hypertension in polycystic ovary syndrome. Arch Mal Coeur Vaiss 2006; 99: 687-690
    PubMedSearch in Google Scholar
  • 63 Carmina E, Lobo RA. Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy Is Associated with Significant Morbidity in Women. J Clin Endocrinol Metab 1999; 84: 1897-1899
    CrossrefPubMedSearch in Google Scholar
  • 64 Wang JX, Davies MJ, Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod 2001; 16: 2606-2609
    CrossrefPubMedSearch in Google Scholar